v3.20.1

Deferred income - Movement in the non-current and current deferred income (Details) - EUR (€) € in Thousands | 12 Months Ended
--- | ---
Dec. 31, 2019 | Dec. 31, 2018 | Dec. 31, 2017
Disclosure of Deferred Income [Line Items] |  |  |
Deferred income, beginning balance | € 149,801 | € 219,892 | € 285,612
Upfront/license fees received |  | 38,874 | 6,000
Upfront received and impact of initial valuation of share subscription | 3,655,416 |  |
Milestones received | 49,727 | 20,965 |
Significant financing component | 6,900 |  |
Revenue recognition of upfront/license fees | (1,009,663) | (148,985) | (71,971)
Revenue recognition of milestones | (51,156) | (64,394) |
Catch-up effect on closing date (1) | 245,883 |  |
Other movements | (46,262) | 229 | 250
Deferred income, ending balance | 3,000,646 | 149,801 | 219,892
Other |  |  |
Disclosure of Deferred Income [Line Items] |  |  |
Deferred income, beginning balance | 308 | 300 | 252
Other movements | (297) | 7 | 48
Deferred income, ending balance | 10 | 308 | 300
IFRS 15 |  |  |
Disclosure of Deferred Income [Line Items] |  |  |
Reclassified from equity following adoption of IFRS 15 |  | 83,220 |
Fee for services segment |  |  |
Disclosure of Deferred Income [Line Items] |  |  |
Deferred income, beginning balance | 471 | 248 | 47
Other movements | (109) | 222 | 202
Deferred income, ending balance | 362 | 471 | 248
Collaboration agreement for filgotinib |  |  |
Disclosure of Deferred Income [Line Items] |  |  |
Deferred income, beginning balance | 145,800 |  |
Deferred income, ending balance |  | 145,800 |
Collaboration agreement for filgotinib | Gilead |  |  |
Disclosure of Deferred Income [Line Items] |  |  |
Deferred income, beginning balance | 145,798 | 213,981 | 285,313
Upfront received and impact of initial valuation of share subscription | 641,663 |  |
Milestones received | 27,317 | 12,417 |
Significant financing component | 6,900 |  |
Revenue recognition of upfront/license fees | (260,207) | (96,809) | (71,333)
Revenue recognition of milestones | (27,092) | (27,623) |
Catch-up effect on closing date (1) | 245,883 |  |
Deferred income, ending balance | 780,261 | 145,798 | 213,981
Collaboration agreement for filgotinib | IFRS 15 | Gilead |  |  |
Disclosure of Deferred Income [Line Items] |  |  |
Reclassified from equity following adoption of IFRS 15 |  | 43,832 |
Gilead collaboration agreement for GLPG 1690 | Gilead |  |  |
Disclosure of Deferred Income [Line Items] |  |  |
Upfront received and impact of initial valuation of share subscription | 666,967 |  |
Revenue recognition of upfront/license fees | (666,967) |  |
Gilead collaboration agreement for drug discovery platform |  |  |
Disclosure of Deferred Income [Line Items] |  |  |
Deferred income, ending balance | 2,220,000 |  |
Gilead collaboration agreement for drug discovery platform | Gilead |  |  |
Disclosure of Deferred Income [Line Items] |  |  |
Upfront received and impact of initial valuation of share subscription | 2,346,787 |  |
Revenue recognition of upfront/license fees | (80,918) |  |
Other movements | (45,856) |  |
Deferred income, ending balance | 2,220,013 |  |
AbbVie collaboration agreement for CF | AbbVie |  |  |
Disclosure of Deferred Income [Line Items] |  |  |
Deferred income, beginning balance | 3,224 |  |
Upfront/license fees received |  | 38,874 |
Milestones received | 22,410 | 8,548 |
Revenue recognition of upfront/license fees | (1,570) | (52,176) |
Revenue recognition of milestones | € (24,064) | (36,771) |
Deferred income, ending balance |  | 3,224 |
AbbVie collaboration agreement for CF | IFRS 15 | AbbVie |  |  |
Disclosure of Deferred Income [Line Items] |  |  |
Reclassified from equity following adoption of IFRS 15 |  | 44,749 |
Servier collaboration agreement for osteoarthritis | Servier |  |  |
Disclosure of Deferred Income [Line Items] |  |  |
Deferred income, beginning balance |  | 5,362 |
Upfront/license fees received |  |  | 6,000
Revenue recognition of upfront/license fees |  |  | (638)
Deferred income, ending balance |  |  | € 5,362
Servier collaboration agreement for osteoarthritis | IFRS 15 | Servier |  |  |
Disclosure of Deferred Income [Line Items] |  |  |
Reclassified from equity following adoption of IFRS 15 |  | € (5,362) |

X
- Definition negative effect of catch up on closing date + References No definition available. + Details
Name: | glpg_CatchUpEffectOnClosingDate1
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Deferred income reclassified from equity + References No definition available. + Details
Name: | glpg_DeferredIncomeReclassifiedFromEquity
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of adjustments to deferred income due to significant financing component. + References No definition available. + Details
Name: | glpg_DeferredIncomeSignificantFinancingComponent
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table. + References No definition available. + Details
Name: | glpg_DisclosureOfDeferredIncomeLineItems
Namespace Prefix: | glpg_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of deferred Income in other movements. + References No definition available. + Details
Name: | glpg_IncreaseDecreaseInOtherDeferredIncome
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue from milestone payments. + References No definition available. + Details
Name: | glpg_MilestonePaymentsReceived
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of revenue recognized on milestone payments. + References No definition available. + Details
Name: | glpg_MilestonePaymentsRevenueRecognized
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of revenue recognized on upfront or license fees. + References No definition available. + Details
Name: | glpg_UpfrontOrLicenseFeesRevenueRecognised
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront Payments and License Fees Received + References No definition available. + Details
Name: | glpg_UpfrontPaymentsAndLicenseFeesReceived
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of upfront received and impact of initial valuation of share subscription during the period. + References No definition available. + Details
Name: | glpg_UpfrontReceivedAndImpactOfInitialValuationOfShareSubscription
Namespace Prefix: | glpg_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of liability representing income that has been received but is not yet earned. [Refer: Revenue] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 78 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_78&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_DeferredIncome
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | glpg_DeferredIncomeAxis=glpg_OtherDeferredIncomeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RetrospectiveApplicationAndRetrospectiveRestatementAxis=ifrs-full_IncreaseDecreaseDueToApplicationOfIFRS15Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=glpg_FeeForServicesSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForFilgotinibMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=glpg_GileadSciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForGlpg1690Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_GileadCollaborationAgreementForDrugDiscoveryPlatformMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForCFMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=glpg_AbbvieMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | glpg_IfrsTypeOfArrangementAxis=glpg_CollaborationAgreementForOsteoarthritisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=glpg_ServierMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |